Cerdulatinib

Cerdulatinib
Clinical data
Other names	PRT062070, PRT2070, DMVT-502
Routes of; administration	By mouth
Identifiers
	IUPAC name 4-(Cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide;
CAS Number	1198300-79-6 [PubChem];
PubChem CID	44595079;
ChemSpider	32822046 ;
UNII	D1LXQ45S1O;
Chemical and physical data
Formula	C20H27N7O3S
Molar mass	445.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N;

Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.[2]

It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).[3]

References

Liu, Delong; Mamorska-Dyga, Aleksandra (2017-07-28). "Syk inhibitors in clinical development for hematological malignancies". Journal of Hematology & Oncology. 10 (1): 145. doi:10.1186/s13045-017-0512-1. ISSN 1756-8722. PMC 5534090. PMID 28754125.
Coffey, Greg; Betz, Andreas; DeGuzman, Francis; Pak, Yvonne; Inagaki, Mayuko; Baker, Dale C.; Hollenbach, Stanley J.; Pandey, Anjali; Sinha, Uma (2014). "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer". The Journal of Pharmacology and Experimental Therapeutics. 351 (3): 538–548. doi:10.1124/jpet.114.218164. ISSN 1521-0103. PMID 25253883.
"Investors - News Release - Portola Pharmaceuticals, Inc". phx.corporate-ir.net. September 25, 2018.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Liu, Delong; Mamorska-Dyga, Aleksandra (2017-07-28). "Syk inhibitors in clinical development for hematological malignancies". Journal of Hematology & Oncology. 10 (1): 145. doi:10.1186/s13045-017-0512-1. ISSN 1756-8722. PMC 5534090. PMID 28754125.

[2] Coffey, Greg; Betz, Andreas; DeGuzman, Francis; Pak, Yvonne; Inagaki, Mayuko; Baker, Dale C.; Hollenbach, Stanley J.; Pandey, Anjali; Sinha, Uma (2014). "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer". The Journal of Pharmacology and Experimental Therapeutics. 351 (3): 538–548. doi:10.1124/jpet.114.218164. ISSN 1521-0103. PMID 25253883.

[3] "Investors - News Release - Portola Pharmaceuticals, Inc". phx.corporate-ir.net. September 25, 2018.

Cerdulatinib

See also

References